# US 2019/0315735 A1 · Cyclopropanamine compound and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315735 A1
- Document ID: US20190315735A1
- Status: Published application
- Kind: A1
- Application number: 16/455,359
- Filed: 2019-06-27
- Published: 2019-10-17
- Earliest claimed: 2014-04-11
- Assignees: Takeda Pharmaceutical Company Limited
- Applicants: Takeda Pharmaceutical Company Limited
- Inventors: Shigemitsu MATSUMOTO; Yasushi HATTORI; Masashi TOYOFUKU; Shinji MORIMOTO; Masaki DAINI; Takuto KOJIMA; Tomohiro KAKU; Mitsuhiro ITO
- Web page: https://patentgrep.com/patent/US20190315735A1

## CPC

- C07D 417/14: containing three or more hetero rings
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/82: in position 3
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 285/08: 1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- C07D 285/135: Nitrogen atoms
- C07D 307/79: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D 307/81: Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 333/40: Thiophene-2-carboxylic acid
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

## Claims

### Claim 1

A compound represented by the formula
wherein
A is an optionally substituted heterocyclic group, or an optionally substituted hydrocarbon group;
B is a ring selected from
(1) a 5- or 6-membered aromatic heterocycle optionally fused with an optionally substituted 5- or 6-membered ring, and
(2) a benzene ring fused with an optionally substituted 5- or 6-membered ring,
wherein the ring represented by B is optionally substituted, and binds, via two adjacent carbon atoms with one atom in between, to a group represented by the formula
and
a group represented by the formula
R1, R2, R3 and R4 are each independently a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;
A and R1 are optionally bonded with each other to form, together with the adjacent nitrogen atom, an optionally substituted cyclic group; and
R2 and R3 are optionally bonded with each other to form, together with the adjacent nitrogen atom, an optionally substituted cyclic group,
or a salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein A is
(1) an optionally substituted heterocyclic group, or
(2) an optionally substituted C3-10 cycloalkyl group,
or a salt thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein B is a ring selected from
(1) a 5- or 6-membered aromatic heterocycle, and
(2) a benzene ring fused with an optionally substituted 5- or 6-membered ring,
wherein the ring represented by B is optionally substituted, and binds, via two adjacent carbon atoms with one atom in between, to a group represented by the formula (II), and a group represented by the formula (III),
or a salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein, in the formula
B is a ring selected from
wherein
X1, X2, X3 and X4 are each independently a carbon atom or a nitrogen atom;
at least one of X1, X2, X3 and X4 is a nitrogen atom;
Y1, Y2 and Y3 are each independently a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom;
at least one of Y1, Y2 and Y3 is a nitrogen atom, an oxygen atom or a sulfur atom; and
Z1, Z2, Z3 and Z4 are each independently a carbon atom or a nitrogen atom, which ring is optionally substituted, or a salt thereof.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R1, R2 and R4 are each independently a hydrogen atom or an optionally substituted C1-6 alkyl group,
or a salt thereof.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein R3 is
(1) a hydrogen atom,
(2) an optionally substituted C1-6 alkyl group,
(3) an optionally substituted C3-10 cycloalkyl group, or
(4) an optionally substituted heterocyclic group,
or a salt thereof.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein, in the formula
A is
(1) (i) a 5- or 6-membered aromatic heterocyclic group or (ii) a 4- to 6-membered non-aromatic heterocyclic group, each of which is optionally substituted by C1-6 alkyl group(s) optionally substituted by halogen atom(s), or
(2) a C3-10 cycloalkyl group optionally substituted by halogen atom(s);
B is a ring selected from
wherein
X1, X2, X3 and X4 are each independently a carbon atom or a nitrogen atom;
at least one of X1, X2, X3 and X4 is a nitrogen atom;
Y1, Y2 and Y3 are each independently a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom;
at least one of Y1, Y2 and Y3 is a nitrogen atom, an oxygen atom or a sulfur atom; and
Z1, Z2, Z3 and Z4 are each independently a carbon atom or a nitrogen atom, which ring is optionally substituted by C1-6 alkyl group(s);
R1 is a hydrogen atom;
R2 is a hydrogen atom;
R3 is
(1) a hydrogen atom,
(2) a C1-6 alkyl group optionally substituted by substituent(s) selected from
(a) a C3-10 cycloalkyl group,
(b) a C6-14 aryl group optionally substituted by carboxy group(s),
(c) a 4- to 6-membered non-aromatic heterocyclic group optionally substituted by C1-6 alkyl group(s) optionally substituted by substituent(s) selected from a carboxy group, and a C6-14 aryl group optionally substituted by carboxy group(s), and
(d) a 5- or 6-membered aromatic heterocyclic group optionally substituted by amino group(s),
(3) a C3-10 cycloalkyl group optionally substituted by substituent(s) selected from an amino group and a halogen atom or
(4) a 4- to 6-membered non-aromatic heterocyclic group optionally substituted by substituent(s) selected from
(a) a C1-6 alkyl group optionally substituted by halogen atom(s),
(b) a C3-10 cycloalkyl group,
(c) a C1-6 alkyl-carbonyl group, and
(d) a C3-10 cycloalkyl-carbonyl group; and
R4 is a hydrogen atom,
or a salt thereof.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein A is
(1) a piperidinyl group, an isoxazolyl group, a pyrazolyl group, a thiadiazolyl group, a thiazolyl group, a tetrahydropyranyl group, an oxetanyl group, an oxadiazolyl group, a thienyl group, a pyridyl group or an oxazolyl group, each of which is optionally substituted by C1-6 alkyl group(s) optionally substituted by halogen atom(s), or
(2) a C3-10 cycloalkyl group optionally substituted by halogen atom(s);
B is a ring selected from
thiophene, thiazole, pyrazole, pyridine, naphthalene and 2,3-dihydrobenzofuran, wherein the ring is optionally substituted by C1-6 alkyl group(s);
R1 is a hydrogen atom;
R2 is a hydrogen atom;
R3 is
(1) a hydrogen atom,
(2) a C1-6 alkyl group optionally substituted by substituent(s) selected from
(a) a C3-10 cycloalkyl group,
(b) a C6-14 aryl group optionally substituted by carboxy group(s),
(c) a tetrahydropyranyl group or a piperidinyl group each optionally substituted by C1-6 alkyl group(s) optionally substituted by substituent(s) selected from a carboxy group, and a C6-14 aryl group optionally substituted by carboxy group(s), and
(d) an oxadiazolyl group optionally substituted by an amino group,
(3) a C3-10 cycloalkyl group optionally substituted by substituent(s) selected from an amino group and a halogen atom or
(4) a tetrahydropyranyl group or a piperidinyl group each optionally substituted by substituent(s) selected from
(a) a C1-6 alkyl group optionally substituted by halogen atom(s),
(b) a C3-10 cycloalkyl group,
(c) a C1-6 alkyl-carbonyl group, and
(d) a C3-10 cycloalkyl-carbonyl group; and
R4 is a hydrogen atom,
or a salt thereof.

### Claim 9 (depends on 1)

The compound according to claim 1, wherein A is
(1) a pyrazolyl group, a thiadiazolyl group or a tetrahydropyranyl group, each optionally substituted by C1-6 alkyl group(s), or
(2) a cyclohexyl group optionally substituted by halogen atom(s);
B is a thiophene ring, which ring is optionally substituted by C1-6 alkyl group(s);
R1 is a hydrogen atom;
R2 is a hydrogen atom;
R3 is a cyclopropylmethyl group, a tetrahydropyranylmethyl group, a cyclobutylmethyl group, a cyclobutyl group or a tetrahydropyranyl group; and
R4 is a hydrogen atom,
or a salt thereof.

### Claim 10 (depends on 1)

The compound according to claim 1, wherein A is a pyrazolyl group, a thiadiazolyl group or a tetrahydropyranyl group, each optionally substituted by C1-6 alkyl group(s),
B is
a thiophene ring, which ring is optionally substituted by C1-6 alkyl group(s);
R1 is a hydrogen atom;
R2 is a hydrogen atom;
R3 is a cyclopropylmethyl group or a cyclobutyl group; and
R4 is a hydrogen atom,
or a salt thereof.

### Claim at position 11

11-13. (canceled)

### Claim 14 (depends on 1)

A medicament comprising the compound according to claim 1 or a salt thereof.

### Claim 15 (depends on 14)

The medicament according to claim 14, which is an LSD1 inhibitor.

### Claim 16 (depends on 14)

The medicament according to claim 14, which is a prophylactic or therapeutic agent for schizophrenia, developmental disorders, autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis, Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration, Huntington's disease, epilepsy or drug dependence.

### Claim at position 15

17-20. (canceled)

### Claim 21

5-((1R,2R)-2-((Cyclobutylmethyl)amino)cyclopropyl)-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide or a salt thereof.
